secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2026-07-07T10:33:23+00:00
Accession:  0001816590-26-000047
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Pathways reports positive 26-week Phase 3 COMP006 data for COMP360 in TRD; NDA on track for Q4 2026
--------------------------------------------------------------------------------

- 39% of 25 mg arm achieved ≥25% MADRS reduction at Week 6, maintained through Week 26.
- Retreatment in Part B enhanced benefit: nearly 30% of responders at Week 6 later achieved remission.
- Safety profile generally well-tolerated; SAEs similar across arms (6.3% vs 5.7%).
- Rolling NDA submission with FDA on track for Q4 2026; launch anticipated H1 2027 subject to approval and DEA rescheduling.
- COMP006 enrolled 581 participants with highly chronic TRD (average depressive episode >3 years).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/0001816590-26-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm
  HTML page:      https://secwatch.observer/filing/0001816590-26-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer